ENTITY
HUTCHMED

HUTCHMED (HCM US)

56
Analysis
Health Care • Hong Kong
HUTCHMED is an innovative, commercial-stage biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing targeted therapies and immunotherapies for cancer and immunological diseases. The company has several novel oncology products marketed in China, with one also approved in the US, Europe, and Japan. HUTCHMED was founded in 2000 and is headquartered in Hong Kong.
more
bullish•HUTCHMED
•28 Jun 2019 16:51

Hutchison-China Meditech (和黄医药) Placement: Big Discount After HK Listing Delayed

HCM, a leading China biotech company, filed a prospectus to sell 8.5 million secondary ADSs. We have covered the company's fundamentals for its...

Logo
705 Views
Share
bullish•ESR
•08 Jun 2019 12:16

ECM Weekly (8 Jun 2019) -ESR Cayman, Shanghai Henlius, Edvantage, JH Education

Aequitas Research puts out a weekly update on the deals that have been covered by Smartkarma Insight Providers recently, along with updates for...

Share
bullish•HUTCHMED
•25 Apr 2019 15:23

Hutchison-China Meditech (和黄医药) H-Share Listing: MNC Partnerships Endorsed Its R&D Capabilities

Hutchison-China Meditech, China-based AIM and NASDAQ dual listed pharmaceutical company, is seeking to raise up to USD 500 million via a Hong Kong...

Logo
892 Views
Share
x